Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
|
|
International Journal of STD & AIDS (10.01.04) Vol. 15; No. 10: P. 697-704 - Monday, October 04, 2004
C. Beyrer, MD, MPH; M. H. Razak, MD, PhD; J. Jittiwutikarn, MD; V. Suriyanon, MD; T. Vongchak, MHS; N. Srirak, PhD; S. Kawichai, PhD; S. Tovanabutra, PhD; K. Rungruengthanakit, MHS; P. Sawanpanyalert, MD, PhD; T. Sripaipan, MHS; D.D. Celentano, ScD
Among study participants, 40.2 percent (750) were admitted for MA detoxification and 59.8 percent (1,115) for opiate (heroin, opium, or both) treatment. MA users were significantly younger, better educated and more likely to be Thai than highland ethnic minorities. Compared to those admitted for opiate or mixed drug treatment, MA users had significantly different sexual risks and STD rates, including lower syphilis seropositivity and higher prevalence of chlamydia. For participants who reported MA use only, use by injection was rare and HIV infection was significantly less common than among all other drug users.
The study's findings show that MA users "are a strikingly different population from opiate/heroin users in northern Thailand." MA users had higher chlamydia rates than opiate users, reflecting their young age, and lower HIV rates than injecting drug users, though these were still elevated. As Thailand is undergoing an epidemic of MA use, the serious public health problem posed by MA use calls for urgent improvement in prevention and treatment methodologies.
041004
AD042026
Copyright © 2004 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
.